Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla B Heavican-Foral, Elisa Mandato, Huiyun Liu, Geoffrey M Nelson, Lu Yang, Renee Chen, Katherine A Donovan, Marcus K Jones, Mikhail Roshal, Yanming Zhang, Ran Xu, Ajit J Nirmal, Salvia Jain, Catharine Leahy, Kristen L Jones, Kristen E Stevenson, Natasha Galasso, Nivetha Ganesan, Tiffany Chang, Wen-Chao Wu, Abner Louissaint, Lydie Debaize, Hojong Yoon, Paola Dal Cin, Wing C Chan, Shannan J Ho Sui, Samuel Y Ng, Andrew L Feldman, Steven M Horwitz, Karen Adelman, Eric S Fischer, Chun-Wei Chen, David M Weinstock, Myles Brown
Gene fusions involving tumor protein p63 gene (TP63) occur in multiple T and B cell lymphomas and portend a dismal prognosis for patients. The function and mechanisms of TP63 fusions remain unclear, and there is no target therapy for patients with lymphoma harboring TP63 fusions. Here, we show that TP63 fusions act as bona fide oncogenes and are essential for fusion-positive lymphomas. Transgenic mice expressing TBL1XR1::TP63, the most common TP63 fusion, develop diverse lymphomas that recapitulate multiple human T and B cell lymphomas...
September 20, 2023: Science Translational Medicine